Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer

Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial

(2017) Patrick Lewicki et al.   JOURNAL OF UROLOGY

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

(2017) Hashim U Ahmed et al.   LANCET

Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice

(2017) J J Tosoian et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy

(2017) Joshua S. Jue et al.   UROLOGY

Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial

(2016) Panu P. Tonttila et al.   EUROPEAN UROLOGY

A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy

(2016) Eduard Baco et al.   EUROPEAN UROLOGY

PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2

(2016) Jeffrey C. Weinreb et al.   EUROPEAN UROLOGY

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

(2016) Freddie C. Hamdy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Urinary Biomarkers for Prostate Cancer

(2016) Jeffrey J. Tosoian et al.   UROLOGIC CLINICS OF NORTH AMERICA

The Prostate Health Index

(2016) Abbey Lepor et al.   UROLOGIC CLINICS OF NORTH AMERICA

The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population

(2016) V. J. Gnanapragasam et al.   Scientific Reports

The Case for Tailored Prostate Cancer Screening: An NCCN Perspective

(2015) Michelle L. McDonald et al.   Journal of the National Comprehensive Cancer Network

The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer

(2015) Stacy Loeb et al.   JOURNAL OF UROLOGY

Prospective Study of Diagnostic Accuracy Comparing Prostate Cancer Detection by Transrectal Ultrasound–Guided Biopsy Versus Magnetic Resonance (MR) Imaging with Subsequent MR-guided Biopsy in Men Without Previous Prostate Biopsies

(2014) Morgan R. Pokorny et al.   EUROPEAN UROLOGY

Overdiagnosis and Overtreatment of Prostate Cancer

(2014) Stacy Loeb et al.   EUROPEAN UROLOGY

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

(2014) Fritz H Schröder et al.   LANCET

Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer

(2014) Anna Bill-Axelson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical use of novel urine and blood based prostate cancer biomarkers: A review

(2013) S. Dijkstra et al.   CLINICAL BIOCHEMISTRY

Multicenter European External Validation of a Prostate Health Index–based Nomogram for Predicting Prostate Cancer at Extended Biopsy

(2013) Giovanni Lughezzani et al.   EUROPEAN UROLOGY

Multicenter Evaluation of [-2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer

(2012) C. Stephan et al.   CLINICAL CHEMISTRY

Radical Prostatectomy versus Observation for Localized Prostate Cancer

(2012) Timothy J. Wilt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of prostate volume measured by transrectal ultrasound and magnetic resonance imaging: Is transrectal ultrasound suitable to determine which patients should undergo active surveillance?

(2012) Brian E. Weiss et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range

(2011) William J. Catalona et al.   JOURNAL OF UROLOGY

Risk Factors for Prostate Cancer Detection After a Negative Biopsy: A Novel Multivariable Longitudinal Approach

(2010) Peter H. Gann et al.   JOURNAL OF CLINICAL ONCOLOGY